C4 THERAPEUTICS INC (CCCC)
Health Care · Targeted protein degradation / small-molecule therapeutics · NASDAQ
Clinical-stage biotech deploying its proprietary TORPEDO platform to develop first-in-class small-molecule targeted protein degraders for oncology, neuroinflammation, and neurodegeneration.
What C4 THERAPEUTICS INC does
C4 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule targeted protein degraders (TPD) using its proprietary TORPEDO platform to degrade disease-causing proteins. The company's lead candidate, cemsidomide, is an orally bioavailable degrader of IKZF1 and IKZF3 in clinical development for multiple myeloma, while CFT8919 targets mutant EGFR in non-small cell lung cancer. C4 is also expanding its pipeline into inflammation, neuroinflammation, and neurodegeneration, including brain-penetrant degraders, and advancing partnerships with Roche and Merck KGaA on additional degrader programs.
Themes: ["Targeted protein degradation (TPD)","Oncology (multiple myeloma, NSCLC)","Inflammation and neuroinflammation","Neurodegeneration","CNS penetrant therapeutics"]
Fundamentals
- Price$4.29 as of 2026-07-09 close
- Market cap$474M as of 2026-07-10
- 1-year return+145.0% as of 2026-07-09 close
- Net margin-297.8% as of 2026-07-10
- ROE-50.7% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-12.4% as of 2026-07-10
- Revenue CAGR (3y)+5.0% SEC XBRL
- Beta2.92 as of 2026-07-10
Key risks (from latest filing)
["Clinical-stage company with no approved products or product revenue; all revenue derived from collaboration agreements, subject to discontinuation or milestone achievement.","Development timelines and regulatory approval uncertain; potential failures in Phase 2 MOMENTUM trial or Phase 1b trials of cemsidomide could delay or prevent commercialization.","Dependence on partnerships with Pfizer, Roche, and other collaborators; loss or termination of these agreements could reduce development capacity and financial resources."]
Competitors & peers
- Kura Oncology (KURA)
- Cullgen
- Nurix Therapeutics (NRIX)
- Protac Therapeutics
- Editas Medicine (NASDAQ: EDIT)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.